UniQure has announced the sale of its commercial manufacturing facility in Lexington, Massachusetts, to Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector production. The deal, valued at $25 million, includes stock and debt. This move comes after UniQure laid off one-fifth of its staff and shuttered another research facility in Lexington in October. As part of the transaction, Genezen will acquire UniQure's commercial gene therapy manufacturing operations, which includes the production of Hemgenix. The sale allows UniQure to outsource the manufacturing of Hemgenix, a gene therapy product. The ticker symbols involved are $QURE and $PFE.
